Rikke Winther

MSc in Pharmacy from Copenhagen University

Role in PharmNovo: Clinical outsourcing lead.

Company: WIN Outsourcing Consult.

Resumé: Rikke is highly specialized and globally experienced within Pre-clinical and Clinical R&D, Business Development and Contract/Outsourcing Management and has worked in the CRO and Pharmaceutical industry within these fields for more than 25 years.

For almost two decades, she headed up the R&D Outsourcing & Contracts Management R&D function at Lundbeck where she was globally responsible for all R&D outsourcing matters covering contractual, operational and relationship related activities with all CROs/vendors as well as complex research collaborations agreements with academia. Rikke has significant experience in developing and executing a broad variety of outsourcing strategies and is a strong negotiator with a win-win approach to retaining positive relationships with all stakeholders.

Prior to her employment at Lundbeck, Rikke worked for five years within bio-analytical research and clinical development in hospital/academia settings. This was followed by four years of employment in a larger CRO (International Project Manager followed by setting up the CRO’s first South East Asia office working as Business Development Manager and Line Manager in Singapore).

Rikke has since 2013 been a Steering Committee member of the Pharmaceutical Contract Management Group (PCMG.org.uk) in Europe.

Member of:

Operational team

Latest news

View all

PharmNovo live at neurology theme event at RedEye

October 25, 2024

PharmNovo live at neurology theme event at RedEye

Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.

October 10, 2024

PharmNovo at the LSX Nordic Congress

PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:

July 17, 2024

17.5 MEUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

PharmNovo presenting at the Global Forum

June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.